Hainan Manaslu Acquisition Corp. priced its $60 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “HMACU” Thursday, August 11, 2022.
The new SPAC aims to focus on targets with high growth potential in the post COVID-19 market including companies targeting vast consumer segments, platform based businesses, and products targeting the younger generation of consumers. Hainan Manaslu is led by Chairman and CEO Zhifan Zhou, CFO Wenyi Shen, and CIO Xun Zhang.
Total SPAC deal count for 2022 year-to-date is now 74. This offering is expected to close on Monday, August 15.
Ladenburg Thalmann & Co. Inc. is acting as sole book-running manager for the IPO. Ellenoff Grossman & Schole LLP is serving as Issuer’s Counsel with Blank Rome LLP serving as Underwriter’s Counsel. Friedman LLP serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.
Real estate marketplace Opendoor (NASDAQ:OPEN) is poised to be the latest de-SPAC to take a double-digit jump on earnings as it heads towards the weekend up +10%, having spiked as high as +27% earlier in the day. The movement comes as the former Social Capital II target reported progress towards profitability despite a high rates...
At the SPAC of Dawn Coinbase (NASDAQ:COIN) notched a surprise profit of over $1.5 billion in the first quarter of 2024, well exceeding estimates, demonstrating the powerful effect of publicly traded ETFs have had on crypto marketplaces since the start of the year. The result has pushed the company to bump up its own guidance...
Online casino and sports company Rush Street (NYSE:RSI) is up +18.4% in trading today on the back of a solid first quarter earnings release, bringing the company’s stock to its highest price since the second half of 2022 (currently $7.60). This makes it the latest in a line of 2020 and 2021 de-SPACs that have...
Mountain Crest V (NASDAQ:MCAG) broke a long dealmaking silence by SPACs this morning, albeit with a non-binding agreement to combine with Seoul-based diagnostic biotech firm CUBEBIO. The term sheet would give the company a $620 million pre-transaction equity value and help accelerate the rollout of CUBEBIO’s CEED-NOVUS cancer screening kit products. The company signed an...
Churchill Capital Corp IX (NASDAQ:CCIXU) announced the pricing of its $250 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “CCIXU”, Thursday, May 2, 2024. The new SPAC will conduct a broad search and has not limited itself to any particular sector or focus, but it plans to...